Biocartis Group NV (BCART) - Net Assets
Based on the latest financial reports, Biocartis Group NV (BCART) has net assets worth €-53.99 Million EUR (≈ $-63.12 Million USD) as of June 2023. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€112.98 Million ≈ $132.09 Million USD) and total liabilities (€166.97 Million ≈ $195.20 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BCART cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-53.99 Million |
| % of Total Assets | -47.78% |
| Annual Growth Rate | N/A |
| 5-Year Change | -134.67% |
| 10-Year Change | -194.77% |
| Growth Volatility | 169.81 |
Biocartis Group NV - Net Assets Trend (2012–2022)
This chart illustrates how Biocartis Group NV's net assets have evolved over time, based on quarterly financial data. Also explore Biocartis Group NV balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Biocartis Group NV (2012–2022)
The table below shows the annual net assets of Biocartis Group NV from 2012 to 2022. For live valuation and market cap data, see BCART market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | €-30.28 Million ≈ $-35.41 Million |
+10.66% |
| 2021-12-31 | €-33.90 Million ≈ $-39.63 Million |
-192.05% |
| 2020-12-31 | €36.82 Million ≈ $43.05 Million |
-56.41% |
| 2019-12-31 | €84.48 Million ≈ $98.76 Million |
-3.29% |
| 2018-12-31 | €87.35 Million ≈ $102.12 Million |
-33.94% |
| 2017-12-31 | €132.24 Million ≈ $154.60 Million |
+36.49% |
| 2016-12-31 | €96.89 Million ≈ $113.27 Million |
-15.69% |
| 2015-12-31 | €114.92 Million ≈ $134.35 Million |
+466.65% |
| 2014-12-31 | €20.28 Million ≈ $23.71 Million |
-36.54% |
| 2013-12-31 | €31.95 Million ≈ $37.36 Million |
-13.17% |
| 2012-12-31 | €36.80 Million ≈ $43.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Biocartis Group NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33335300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €930.00K | % |
| Other Comprehensive Income | €-219.57 Million | % |
| Other Components | €631.72 Million | % |
| Total Equity | €-30.28 Million | 100.00% |
Biocartis Group NV Competitors by Market Cap
The table below lists competitors of Biocartis Group NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mount Ridley Mines Ltd
AU:MRD
|
$27.24 Million |
|
WI Co. Ltd.
KQ:073570
|
$27.24 Million |
|
Shivam Autotech Limited
NSE:SHIVAMAUTO
|
$27.26 Million |
|
GeneMatrix Inc
KQ:109820
|
$27.26 Million |
|
PNC Technologies co. Ltd
KQ:237750
|
$27.21 Million |
|
Siili Solutions Oyj
HE:SIILI
|
$27.21 Million |
|
4C Group AB
ST:4C
|
$27.19 Million |
|
IL&FS Investment Managers Limited
NSE:IVC
|
$27.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biocartis Group NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -33,897,000 to -30,284,000, a change of 3,613,000.
- Net loss of 65,381,000 reduced equity.
- New share issuances of 23,055,000 increased equity.
- Other comprehensive income increased equity by 369,000.
- Other factors increased equity by 45,570,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-65.38 Million | -215.89% |
| Share Issuances | €23.05 Million | +76.13% |
| Other Comprehensive Income | €369.00K | +1.22% |
| Other Changes | €45.57 Million | +150.48% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Biocartis Group NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | €0.78 | €0.29 | x |
| 2013-12-31 | €0.67 | €0.29 | x |
| 2014-12-31 | €0.43 | €0.29 | x |
| 2015-12-31 | €2.64 | €0.29 | x |
| 2016-12-31 | €2.01 | €0.29 | x |
| 2017-12-31 | €2.50 | €0.29 | x |
| 2018-12-31 | €1.46 | €0.29 | x |
| 2019-12-31 | €1.31 | €0.29 | x |
| 2020-12-31 | €0.57 | €0.29 | x |
| 2021-12-31 | €-0.51 | €0.29 | x |
| 2022-12-31 | €-0.50 | €0.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biocartis Group NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -113.74%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-63.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -120.74% | -1251.23% | 0.05x | 1.80x | €-48.11 Million |
| 2013 | -111.47% | -427.46% | 0.14x | 1.88x | €-38.82 Million |
| 2014 | -44.96% | -107.56% | 0.16x | 2.61x | €-11.15 Million |
| 2015 | -34.63% | -298.48% | 0.09x | 1.29x | €-51.29 Million |
| 2016 | -51.38% | -411.45% | 0.09x | 1.46x | €-59.47 Million |
| 2017 | -31.73% | -200.22% | 0.12x | 1.37x | €-55.18 Million |
| 2018 | -55.13% | -173.14% | 0.20x | 1.60x | €-56.89 Million |
| 2019 | -75.84% | -171.10% | 0.14x | 3.18x | €-72.52 Million |
| 2020 | -170.90% | -145.92% | 0.20x | 5.72x | €-66.62 Million |
| 2021 | 0.00% | -148.07% | 0.34x | 0.00x | €-68.08 Million |
| 2022 | 0.00% | -113.74% | 0.50x | 0.00x | €-62.35 Million |
Industry Comparison
This section compares Biocartis Group NV's net assets metrics with peer companies in the Diagnostics & Research industry.
No peer company data available for comparison.
About Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progres… Read more